D&A at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s D&A?
- Recursion Pharmaceuticals, Inc. (RXRX) reported D&A of $19.67M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s D&A increased by 1.8% year-over-year, from $19.33M to $19.67M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s D&A has grown at a 77.6% compound annual growth rate (CAGR), from $8.41M to $83.7M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.